Triple incretin agonist paired with an amylin analog, studied in metabolic models.
For research use only. Not for human or veterinary use. No claims of safety, efficacy or therapeutic benefit.
Triple-receptor metabolic signaling combined with amylin-related satiety research. Separate weight-management trials of the ingredients do not establish the effectiveness, tolerability or dose relationship of this combination.
The cited evidence concerns individual ingredients or related fragments. No controlled study of this exact Avitus blend was identified; synergy and clinical benefits remain unestablished.
PMID: 37366315, 34798060
Contact the Avitus team to confirm available presentations, product specifications and pricing for your research requirements.